Drugs / Nasovac-S
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02972957 | Jan 2017 → Dec 2018 | influenza | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nasovac-S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02972957 ↗ |
| Modality | Vaccine | “intranasal live attenuated influenza vaccine (LAIV; Nasovac-S, Serum Institute of India Pvt. Ltd.)” NCT02972957 ↗ |